Overview

A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin. This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Adherex Technologies, Inc.
Treatments:
Melphalan